Document Detail

Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients.
MedLine Citation:
PMID:  1378134     Owner:  NLM     Status:  MEDLINE    
The efficacy, safety, and pharmacokinetics of carvedilol were investigated in an open trial performed on 13 hypertensive patients with chronic renal failure and six additional patients requiring hemodialysis. In hypertensive renal failure patients, treatment with carvedilol (5 mg/day) for 1 week produced a significant decrease in blood pressure (from 172/101 to 146/84 mm Hg) but did not change the heart rate. The pharmacokinetics of carvedilol did not change with repeated administration, and there was no accumulation of this drug. In hemodialysis patients with hypertension, the pharmacokinetics of carvedilol after a single dose of 10 mg did not vary between dialysis and nondialysis days, and blood pressure decreased significantly on both days. In addition, there was no accumulation of carvedilol during a 4-week trial of therapy, and blood pressure was decreased significantly from 170/93 to 145/83 mm Hg. There were no side effects and no abnormal laboratory findings noted during the trial. These results indicate that carvedilol is an effective and safe agent for hypertensive patients with chronic renal failure and for hemodialysis patients with hypertension and that dosage adjustments are probably not required in these clinical situations.
H Masumura; S Miki; Y Kaifu; W Kitajima; Y Abe
Related Documents :
2064494 - The treatment of mild hypertension study. a randomized, placebo-controlled trial of a n...
11416644 - The effects of candesartan cilexetil in isolated systolic hypertension: a clinical expe...
2468864 - Prolonged calcium channel blocker therapy of hypertension.
6874124 - Blood pressure behaviour in hemodialysis patients treated for 10 years.
623584 - Aerodynamic forces exerted on an articulated human body subjected to windblast.
7282954 - Effect of sympathectomy on arterial and venous changes in renal hypertensive rats.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  19 Suppl 1     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1992  
Date Detail:
Created Date:  1992-08-07     Completed Date:  1992-08-07     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S102-7     Citation Subset:  IM    
Department of Pharmacology, Kagawa Medical School, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / pharmacokinetics*,  therapeutic use
Blood Pressure / drug effects
Blood Urea Nitrogen
Carbazoles / pharmacokinetics*,  therapeutic use
Creatinine / blood
Heart Rate / drug effects
Hypertension / complications,  drug therapy*,  metabolism
Kidney Failure, Chronic / complications*,  metabolism
Middle Aged
Propanolamines / pharmacokinetics*,  therapeutic use
Renal Dialysis*
Vasodilator Agents / pharmacokinetics*,  therapeutic use
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Carbazoles; 0/Propanolamines; 0/Vasodilator Agents; 0K47UL67F2/carvedilol; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Beta-blocking agents with vasodilating action.
Next Document:  Effects of carvedilol during exercise.